Oral Zeolite Therapy for Management of Mild to Moderate Lead Poisoning: A Randomized Clinical Trial

Lead poisoning can present with a spectrum of symptoms, from fatigue to severe multiorgan complication; and Zeolite is known for its ability to remove heavy metals. This study aimed to assess the impact of zeolite on serum lead levels and blood parameters of patients with mild to moderate lead poisoning.

This double-blind randomized clinical trial evaluated the effects of zeolite on serum lead levels of patients with mild to moderate lead poisoning, conducted between August 2022 and December 2022. The intervention group received oral zeolite tablets in addition to standard treatment, while the control group received only standard treatment. The impact of zeolite administration on serum lead levels and blood parameters was investigated using an appropriate statistical test.

80 patients with a mean age of 39.84 ± 11.94 (range: 23-75) years were randomized (78.75% male). The two groups were similar regarding age (p = 0.329), sex (p = 0.785), baseline serum lead levels (p = 0.596), and liver enzymes (p = 0.648).The Zeolit group had lower serum lead levels (25.22 ± 13.26 vs. 37.68 ± 15.34; p < 0.001, ES: 0.869) and hematocrit (36.21 ± 7.83 vs. 39.53 ± 5.60; ES: 0.488; p = 0.032) after 2 weeks of treatment.

Zeolite tablets show considerable promise as an adjunct therapy for mild to moderate lead poisoning. They effectively lower serum lead levels without adverse effects. This intervention could reduce the metal burden in the bloodstream and mitigate lead-induced multiorgan damage, offering a more effective and less invasive treatment option.